LONDON--(BUSINESS WIRE)--Technavio has been monitoring the cancer cachexia therapeutics market and it is poised to grow by USD 568.85 million during 2019-2023, progressing at a CAGR of 6% during the ...

Immune checkpoint inhibitors (ICIs), including antibodies against the programmed cell death protein 1/ligand 1 (PD-1/L1) ...

PH284 nasal spray increased hunger in cancer cachexia patients, showing a 71% improvement in subjective hunger scores compared to baseline. The phase 2A study demonstrated PH284's safety, with no ...

The investigational drug ponsegromab — which inhibits growth differentiation factor 15 (GDF-15), a cytokine elevated in cancer cachexia — increases weight, appetite, and physical activity in patients ...

Please provide your email address to receive an email when new articles are posted on . Patients who developed cancer cachexia after CAR-T for lymphoma had poorer survival. They also had worse ...

Please provide your email address to receive an email when new articles are posted on . Patients with cancer cachexia assigned ponsegromab gained significantly more weight than those assigned placebo.

"Cancer-related cachexia and sarcopenia occur in hematologic malignancies, not just gastrointestinal carcinomas and head and neck cancers. Their presence affects all aspects of diagnosis and treatment ...

In cachexia, liver metabolism is fundamentally reprogrammed. One gene, which normally regulates the liver’s activity throughout the day, ceases to function properly. Using a mouse model, the ...

Explore how nutrition plays a crucial role in cancer prevention, treatment, and recovery, emphasizing the power of a balanced diet.